Acrivon Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACRV Nasdaq 2836 acrivon.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acrivon Therapeutics, Inc.

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer - Aug 31st, 2026 6:30 am
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy - Aug 24th, 2026 10:00 am
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts - Aug 12th, 2026 2:05 pm
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study - Aug 5th, 2026 6:30 am
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference - Jul 21st, 2026 2:30 pm
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - May 21st, 2026 5:30 am
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 15th, 2026 2:00 pm
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts - May 13th, 2026 2:10 pm
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities - Apr 17th, 2026 2:00 pm
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Mar 19th, 2026 5:21 am
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors - Mar 17th, 2026 3:54 pm
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why - Mar 3rd, 2026 10:00 am
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Feb 27th, 2026 9:47 am
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Feb 24th, 2026 6:00 am
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress - Feb 23rd, 2026 6:00 am
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory - Feb 18th, 2026 6:00 am
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares - Jan 18th, 2026 6:18 am